A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer
Conditions: Breast Neoplasms; Breast Diseases; Capecitabine; HER2-positive Breast Cancer; HER2 Positive Breast Carcinoma Interventions: Drug: RC48-ADC; Drug: Lapatinib; Drug: Capecitabine Sponsor: RemeGen Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | HER2 | Research | Study | Xeloda